NCT00925106

Pharmacokinetics Of Celecoxib Test Formulations

A Pilot, Open-Label, Randomized, Crossover, Pharmacokinetic Study Of Enhanced Bioavailability Celecoxib Formulations D1, D2 And D3 In Healthy Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 16 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The pharmacokinetics of new formulations of celecoxib are being evaluated. They are expected to provide more favorable bioavailability characteristics than the present commercial formulation.

Conditions

• Healthy Volunteers

Interventions

Type	Name	Description
DRUG	Celebrex capsule	Single dose 200 mg commercial Celebrex capsule
DRUG	Test formulation D1	Single dose 150 mg celecoxib as formulation D1
DRUG	Test formulation D2	Single dose 150 mg celecoxib as formulation D2
DRUG	Test formulation D3	Single dose 150 mg celecoxib as formulation D3

Timeline

• Start date: 2009-07-01
• Primary completion: 2009-08-01
• Completion: 2009-08-01
• First posted: 2009-06-19
• Last updated: 2021-02-02

Locations

1 site across 1 country: United States